Korea Biobank Network
detail content area
Masan National Tuberculosis Hospital
Affiliated with Korea's Ministry of Health and Welfare, MNH was established to contribute to curing tuberculosis (TB) and improving the health of the nation. MNH fulfills this role by developing treatment techniques for intractable TB through TB treatment and clinical research. Every year, the hospital treats 130,000 inpatients and 6,000 outpatients, performs 100 lung surgeries, conducts research in relation to intractable TB, and publishes approximately 10 papers in domestic and overseas journals. The hospital's operations depend entirely on national funds, and no treatment fees are borne by patients seeking healthcare.
Mycobacterium tuberculosis reported infects a third of the world's total population, of whom 90% to 95% could combat the bacteria with their effective immune system. Nonetheless, approximately 5% to 10% of individuals develop TB within one to three years (active TB). These people contract TB because they lack aneffective immune response, and as a result, Mycobacterium tuberculosis continues to grow and spread to other organs outside of the lungs. Additionally, clinical TB symptoms arise.
In cases where TB does not develop, the growth of Mycobacterium tuberculosisis completely prevented by the immune response. However, only the bacteria's growth is prevented; itisnot killed by the immune response. It continues to exist in a non-replicating persistent state within the body. When their immune system is impaired, individuals carrying the TB bacteria in this persistent state are reported to show recurrence in approximately 5% to 10% of cases.
Studies have not confirmed how Mycobacterium tuberculosis controls active TB infection and the persistent state. Further, the physiological states of the bacteria remain unknown, as are the factors causing the bacteria to stop growing and maintain a particular state during active TB or the persistent state. Even the effect of the host's immune system on the growth of the bacteriais not known. In conducting research to understand these mechanisms, the greatest difficulty is the lack of samples that include these TB infection patterns.
The TB Tissue Bank focuses on researching how various clinical patterns are presented, providing better diagnosis and treatment methods for drug-resistant TB, and assisting studies that are developing new TB medications.
Current Status of Human Bioresources
TB is a chronic infectious disease caused by the Mycobacterium tuberculosis complex. TB infection can be contracted from tiny droplets of saliva from pulmonary TB patients who have Mycobacterium tuberculosis. However, not everyone infected with the bacteria develops TB. TB can cause disease in the majority of tissues and organs, including the lungs, kidneys, nerves, and bones. However, of these, Mycobacterium tuberculosis usually causes pulmonary TB by infecting the lung tissue, which explains the use of the term "TB" to refer to "pulmonary TB."
In accordance with hospital guidelines, physicians-in-chargeat MNH ask for the willful consent of patients to provide samples, taken from specimens for treatment and diagnosis. Samples extracted are used in routine biochemical tests or tests for microorganisms. Subsequently, the remaining samples are gathered to form a specimen biobank. The types of sample extracted include sputum, serum, urine, lung tissue, and Mycobacterium tuberculosis isolated from the sputum.
Between 2009 and 2016, 2,656 patients gave consent to the TB Bio Bank (684 females, 1,972 males), and the total number of samples stored in the biobank from these individuals was 19,152. Of the stored samples, 9,619 were sputum, 7,311 were serum, 2,219 were urine, and 3 were lung tissue. To date, approximately 8,000 samples of Mycobacterium tuberculosis lines have been isolated from TB patients.
Clinical Research Center, Masan National Hospital, 215 Gapo-ro, Masanhappo-gu, Changwon-si, Gyeongsangnam-do, Korea (51755)
- E-mail: email@example.com
- Homepage: http://www.mnth.go.kr